• Corpus ID: 36870540

Enzymatic Reactions of Methionine Sulfoximine

  title={Enzymatic Reactions of Methionine Sulfoximine},
  author={Arthur and J. and Ľ. and Cooper},
L-Methionine sulfoximine is a substrate of L-amino acid oxidase (Crotalus adamanteus), glutamine transaminase, and y-cystathionase. In the reaction catalyzed by L-amino acid oxidase, methionine sulfoximine is converted to oc-imino-y-methylsulfoximinylbutyrate, which undergoes rapid y elimination yielding methane sulfinimide and 2-imino-3-butenoic acid. Methane sulfinimide is converted to methane sulfonamide, methane sulfinic acid, and methane sulfonic acid; 2-imino&butenoic acid is hydrolyzed… 

Figures from this paper

Cysteine S-conjugate b-lyases Review Article
Cysteine S-conjugate -lyases are pyridoxal 50-phosphatecontaining enzymes that catalyze -elimination reactions with cysteine S-conjugates that possess an electron-withdrawing group attached at the
Possible treatment of end-stage hyperammonemic encephalopathy by inhibition of glutamine synthetase
Inhibition of brain glutamine synthetase by MSO (or other GS inhibitors) may have therapeutic benefit in ALF, and it is possible to chronically maintain cerebral GS activity in mice at low levels byMSO treatment without any obvious untoward effects.
Inhibition of glutamine synthetase during ammonia exposure in rainbow trout indicates a high reserve capacity to prevent brain ammonia toxicity
The changes in amino acid levels suggest that multiple enzymatic pathways can supply glutamate for the production of glutamine via GSase during ammonia exposure and that alternative transaminase pathways can be recruited for ammonia detoxification.
Astrocyte glutamine synthetase: Importance in hyperammonemic syndromes and potential target for therapy
The physiology, pathology, and biochemistry of ammonia are reviewed and it is shown how these elements interact to constitute a syndrome that clinicians refer to as hyperammonemic encephalopathy (i.e., acute liver failure, fulminant hepatic failure, chronic liver disease).


Sic. 89,' 1205%i 211'
  • 1966
Br . Med . J . 2 , 885 - 887 ; ( 1947 )
  • Br . Med . J .
  • 1946